By The RX Index Editorial Team · Last verified: April 26, 2026

Medicare GLP-1 Bridge Program Providers: Who Can Actually Help in 2026?

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We are not affiliated with CMS, Medicare, or any of the clinical providers on this page. We are not a medical practice and do not provide medical advice.

What we actually verified for this page

Last verified: April 26, 2026. Sources cited inline.

Quick start: which path fits your situation?

What are Medicare GLP-1 Bridge program providers, exactly?

A Medicare GLP-1 Bridge program provider is any licensed medical provider — MD, DO, NP, or PA — who can document your eligibility, write the prescription for an eligible product (Foundayo, Wegovy, or Zepbound KwikPen), and submit a prior authorization request to the Bridge central processor. CMS does not maintain a special “Bridge provider network.”

If you’ve been searching for a directory of approved Bridge clinics, you can stop. There isn’t one. CMS chose to build the Bridge outside the standard Part D benefit on purpose — it operates through a single central processor that any licensed clinician can submit to, regardless of whether that clinician is in your Part D plan’s network or accepts Medicare assignment for their own visits.

The two requirements (and why most clinicians meet them)

That’s it. Those are the federal requirements.

The hidden rule that breaks most articles

Competitors keep flattening this: does the provider have to accept Medicare?

For Bridge medication coverage: no. CMS is explicit on that. For everything else around the Bridge — the office visit, the labs, the follow-up — yes, it matters a lot. If you go to an out-of-network clinic, the medication might still process at $50 through your pharmacy, but the visit might cost $200–$400 out of pocket. That’s the trap a lot of people will fall into when telehealth GLP-1 platforms market “Bridge support” without explaining what they will and won’t bill to Medicare.

Our framing throughout this guide: separate the medication path from the visit path. They run on different rules.

Who qualifies for the Medicare GLP-1 Bridge?

To use the Medicare GLP-1 Bridge, you need to be enrolled in a standalone Part D Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) for calendar year 2026. You also need to meet one of three clinical tiers based on BMI and qualifying conditions, measured at the time GLP-1 therapy was initiated — not necessarily your BMI today.

Plan eligibility

Clinical eligibility — the three tiers

CMS lists three pathways. You only need to meet one.

Source: CMS Medicare GLP-1 Bridge FAQ. For reference: a 5’6” person at 217 lbs has a BMI of approximately 35. A 5’10” person at 209 lbs has a BMI of approximately 30.

Which medications are covered through the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge covers all formulations of Foundayo®, all formulations of Wegovy®, and only the KwikPen® formulation of Zepbound® when prescribed for weight loss. Zepbound single-dose vial and single-dose pen are explicitly not available through the Bridge. Compounded GLP-1 medications are not covered.

Indication routing — Bridge vs. standard Part D

A GLP-1 prescription for weight loss goes through the Bridge, but the same medication for a different FDA-approved indication goes through your regular Part D plan.

Who is the best provider path for the Medicare GLP-1 Bridge?

For most people, the best first move is the clinician who already prescribed your medication or your existing primary care doctor. We are deliberately not naming a single “best” provider — the right answer depends on whether you already have a doctor, what plan you’re on, and where you live.

Which online GLP-1 providers look most Bridge-ready right now?

Form Health, knownwell, and Shapely are the strongest publicly verifiable Medicare-facing online GLP-1 providers as of April 2026. Ro is the best non-Bridge fallback for readers who need FDA-approved cash-pay options.

Do providers have to accept Medicare to submit Bridge paperwork?

No — not for the Bridge medication itself. CMS says the prescriber doesn’t need to be enrolled in Medicare to submit a Bridge prior authorization, only that they must not be on the Preclusion List. But Medicare acceptance still matters for visit costs, lab fees, and ongoing care, which run on a separate billing track from the Bridge medication.

What this means in practice — two scenarios

The medication path is identical. The visit path is everything.

What to ask any provider before you book

“Hi — I’m a Medicare beneficiary and I’m asking about the Medicare GLP-1 Bridge program. I have two questions before I book.

1. Will your clinicians submit a prior authorization for the Bridge to CMS’s central processor for an eligible Part D beneficiary? If not, do you support standard Part D prior authorizations for indications like type 2 diabetes or sleep apnea?

2. Are your visits and follow-up labs billed to Medicare directly, or do I pay cash for the visit even if my medication runs through the Bridge?”

Two questions. The clinic’s answers tell you whether they’re a fit.

How does the Medicare GLP-1 Bridge prior authorization actually work?

Your provider submits the Bridge prior authorization request and prescription to a single CMS central processor — not to your Part D plan. CMS has selected Humana to operate the central processor, using the existing LI NET infrastructure. Once the PA is approved, your pharmacy submits the claim using BIN 028918 and PCN MEDDGLP1BR.

The plain-English workflow

1. 1

   You confirm you likely qualify — one of three BMI/condition tiers, on an eligible Part D plan.

2. 2

   Your provider documents — your BMI at therapy initiation, qualifying condition if applicable, and current medication need.

3. 3

   Your provider submits the Bridge PA — to the CMS central processor. This is not the same submission as a regular Part D prior authorization. CMS will release detailed submission portal instructions in Spring 2026.

4. 4

   The central processor reviews the PA — Bridge-specific turnaround targets have not been published as of late April 2026.

5. 5

   Your pharmacy fills the prescription — using BIN 028918 and PCN MEDDGLP1BR. Pharmacies don't need to opt in — CMS will provide processing instructions to all pharmacies in the coming months.

6. 6

   You pay $50 — at pickup.

Pharmacy payer-sheet details — print this and keep it with your Medicare card

Pharmacy script — for the day your prescription is ready

“This is a Medicare GLP-1 Bridge prescription, not a standard Part D claim. The Bridge uses BIN 028918 and PCN MEDDGLP1BR. The processor is SS&C Health, routed through RelayHealth. The CMS payer sheet is dated March 16, 2026 and is on cms.gov. The provider relations help desk is 844-673-0910. Can you check your processing instructions?”

What should you bring before asking a provider for Bridge help?

Walk in with documentation, not just intent. Bring your Medicare Part D card, your BMI at the time GLP-1 therapy started (or your starting weight and height if you’ve never been on one), records of any qualifying conditions, current medication list, and any prior authorization or denial letters from previous attempts. This is the single biggest thing you can do to avoid a denied first PA submission.

How much does the Bridge cost, and what does the $50 copay not cover?

The Medicare GLP-1 Bridge medication copay is $50 per monthly supply. That’s the medication cost — not your visit cost, not labs, not the membership fee for any telehealth platform. The $50 copay does not count toward your Part D deductible, does not count toward the $2,100 Part D out-of-pocket cap, cannot be reduced by manufacturer coupons, and is not eligible for the Part D Low-Income Subsidy.

Cost comparison — verified base values

The math is clear: the Bridge is dramatically cheaper than any cash-pay path if you qualify. The cash-pay path only makes sense for readers who don’t qualify, can’t wait, or have specific reasons (their doctor declined, they want to try the program before July 2026 launch).

What if your doctor, your plan, or your pharmacy is confused?

Confusion is likely, especially in the first six months of the program. The fastest fix is to identify which step is broken and address that step specifically. Here are scripts for the four most common confusion points.

What happens after December 31, 2027?

As of CMS’s most recent guidance, the Medicare GLP-1 Bridge runs through December 31, 2027. CMS originally planned for the BALANCE Model to take over starting January 1, 2027. On April 21, 2026, CMS announced that BALANCE would not implement in Medicare Part D in 2027, and the Bridge was extended through 2027 to continue coverage. What happens after December 2027 has not yet been announced.

What to monitor through 2027

• •CMS Bridge page updates (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)
• •Medicare Open Enrollment (October 15 – December 7 each year) — Part D plans may add or change GLP-1 coverage
• •Your Part D plan's annual notice of change — sent each fall
• •Provider-side updates from any telehealth platform you're using
• •Eligible drug and NDC list — CMS may update which products and formulations are covered

What to do now if you’re worried about post-2027 coverage

Frequently asked questions about Medicare GLP-1 Bridge program providers

How we built this guide

We compared CMS Medicare GLP-1 Bridge rules, the CMS GLP-1 Bridge payer sheet (NCPDP claim billing/rebill payer sheet, dated 3/16/2026), the CMS BALANCE Model FAQ, FDA statements on FDA-approved versus compounded drugs, manufacturer savings program restrictions, KFF policy analysis, NCPA pharmacy guidance, and public provider pages. We separated three claim types throughout: (1) verified CMS rules, cited to cms.gov directly; (2) provider-stated commercial facts, cited to each provider’s public site; and (3) editorial judgments — including which provider path fits which reader — explicitly framed as our editorial conclusions based on the verified facts above.

We marked Bridge-specific provider integration as [NEEDS VERIFICATION] everywhere we couldn’t confirm it directly, because we’d rather be useful and transparent than confident and wrong.

Material connections: The RX Index earns affiliate commissions when readers sign up with certain telehealth providers, including Form Health, knownwell, Shapely, Ro, and Sesame Care. Bridge access through your existing doctor pays us nothing — and is the cheapest path for most readers, which is why we recommend it first.

Sources

1. Centers for Medicare & Medicaid Services — Medicare GLP-1 Bridge
2. CMS GLP-1 Bridge Payer Sheet (NCPDP Version D, dated 3/16/2026)
3. CMS — BALANCE Model FAQ
4. CMS — Preclusion List overview
5. KFF — What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries
6. KFF — CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage (April 2026)
7. NCPA — CMS kicks the can on weight loss GLP-1 drugs (April 23, 2026)
8. Reuters — Delay in Medicare pilot for obesity drugs may not hurt near-term demand
9. Form Health — FAQs (Medicare acceptance)
10. knownwell — Insurance
11. Shapely — Medicare Coverage
12. Ro — Body Program
13. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
14. NovoCare — Wegovy Savings Offer
15. Zepbound — Savings Options

Last verified: April 26, 2026 · By The RX Index Editorial Team · Next re-verification: quarterly and after any CMS update. This page is not medical or legal advice. The RX Index is not affiliated with CMS, Medicare, Humana, Form Health, knownwell, Shapely, Ro, Novo Nordisk, or Eli Lilly. If something here is out of date, please let us know and we’ll fix it within 48 hours.